LSPN Connect: micro-managing with Pendulum Therapeutics
With any rapidly-developing field, particularly the life sciences, the importance of a coherent IP strategy cannot be ignored.
Federal Circuit won’t revisit revived Illumina DNA test patents
The US Court of Appeals for the Federal Circuit will not revisit its ruling that saved the patent eligibility of two DNA test patents owned by biotechnology company Illumina, after the court rejected an en banc request from a subsidiary of Roche.
KIPA hires former Decode Genetics director
IP boutique KIPA has strengthened its team with the addition of Iceland-based patent attorney Thorlakur Jonsson.
Medit scores win in 3Shape patent battle
South Korean medical devices manufacturer Medit has prevailed in a patent infringement lawsuit brought by Danish rival 3Shape in Germany.
Fed Circuit orders new Bio-Rad trial, but upholds $24m award
The US Court of Appeals for the Federal Circuit has partially lifted an injunction on 10X Genomics, but the biotech company must still pay almost $24 million for infringing a Bio-Rad patent.
Children’s hospital researcher admits selling trade secrets to China
A former researcher at the research institute of the Nationwide Children’s Hospital in Ohio has pleaded guilty to conspiring to steal scientific trade secrets to sell in China.
Sanofi, GSK secure $2.1bn from US in COVID-19 vaccine deal
The US government has agreed to pay up to $2.1 billion to Sanofi and GSK for the development and delivery of 100 million doses of a COVID-19 vaccine.
Fake botox seized in Cincinnati
US authorities have seized thousands of dollars worth of counterfeit Botox injections in shipments in a Cincinnati port, the US Customs and Border Protection (CBP) office announced yesterday, July 30.
Humira buyers appeal AbbVie ruling to Seventh Circuit
Buyers of AbbVie’s arthritis treatment Humira have appealed against an Illinois judge’s decision to dismiss their class action antitrust suit to the US Court of Appeals for the Seventh Circuit.
LSPN Connect: CRISPR, IP headaches and ‘deplorable’ diversity
The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.
